Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Eli Lilly And Co (LLY) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs Eli Lilly And Co — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $19.93, while Eli Lilly And Co trades at $1,153.5 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while YieldMax COIN Option Income Strategy ETF pays none. Which is the better fit depends on your goals.

CONYLLY
Sector
Income / Options OverlayHealth
52-Week High
$103.20$1.24K
52-Week Low
$18.43$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.

The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY